UNSPSC 51171839: Hydroxyzine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H27ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 30S50YM8OG, chemically known as ethanol, 2-(2-(4-(p-chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)- but generally known as hydroxyzine, which bears US NIH Compound Identifier 3658. European Medicines Agency schedules Hydroxyzine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08088MIG.

UNSPSC 51171839 Hydroxyzine is a Commodity code that encompasses individual pharmaceutical products purchased by state and local government agencies, including correctional departments, health and human services commissions, and cooperative purchasing alliances. State and local buyers use this code to procure specific drugs for institutional populations—offenders in community supervision programs, Medicaid beneficiaries, and employees covered under state health plans. The scope of work extends from direct pharmaceutical supply through manufacturer contracts and wholesaler distribution networks to integrated clinical services such as specimen collection, drug testing, and result reporting that depend on the drug itself as a component of a larger testing or treatment protocol. Issuing bodies range from county corrections departments operating testing programs to state health agencies managing pharmacy benefits and multistate cooperative purchasing organizations aggregating demand across member jurisdictions.

Recent activity concentrates in Texas and the Upper Midwest, with three recent solicitations spanning different procurement models. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026 (due July 23, 2026) for offender specimen collection and drug testing services including immunoassay screening with confirmation methodologies; the estimated contract value is $600,000 over two years with optional renewal. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 seeking vendor capabilities for a Direct-to-Manufacturer Prescriptions program operating outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers to participating state and local facilities in Minnesota and Oregon. The MMCAP solicitation emphasizes price competitiveness weighted at 75 percent of evaluation, with vendors required to maintain cGMP and Drug Supply Chain Security Act compliance and execute chargebacks through authorized wholesaler partners.